| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 17.242 | 14.632 | 44.994 | 51.084 | 34.432 | 20.178 | 17.905 | 18.008 | 16.145 | 35.997 |
| Total Income - EUR | 18.407 | 16.311 | 45.628 | 52.812 | 34.626 | 23.020 | 18.070 | 56.024 | 16.605 | 36.000 |
| Total Expenses - EUR | 43.449 | 7.979 | 18.331 | 26.934 | 13.765 | 14.661 | 3.335 | 6.045 | 5.088 | 4.492 |
| Gross Profit/Loss - EUR | -25.042 | 8.332 | 27.297 | 25.878 | 20.861 | 8.359 | 14.735 | 49.979 | 11.517 | 31.508 |
| Net Profit/Loss - EUR | -25.042 | 8.332 | 23.876 | 25.092 | 20.516 | 8.007 | 14.200 | 48.345 | 9.875 | 26.403 |
| Employees | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Eulogosprim Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 2.449 | 12.302 | 10.086 | 6.341 | 2.501 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 60.526 | 58.856 | 74.080 | 95.715 | 109.140 | 91.917 | 86.825 | 69.651 | 50.201 | 63.536 |
| Inventories | 0 | 0 | 12.042 | 10.550 | 10.711 | 10.395 | 10.165 | 10.196 | 10.165 | 10.108 |
| Receivables | 59.609 | 58.364 | 58.263 | 81.089 | 85.566 | 66.604 | 65.970 | 52.866 | 33.157 | 47.893 |
| Cash | 917 | 492 | 3.775 | 4.077 | 12.863 | 14.918 | 10.691 | 6.589 | 6.879 | 5.534 |
| Shareholders Funds | 23.534 | 31.626 | 24.619 | 49.259 | 53.738 | 47.678 | 43.840 | 48.442 | 46.174 | 57.242 |
| Social Capital | 90 | 89 | 88 | 86 | 84 | 83 | 81 | 81 | 81 | 80 |
| Debts | 39.441 | 39.532 | 59.548 | 52.797 | 57.904 | 44.239 | 42.985 | 21.209 | 4.026 | 6.294 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "7020 - 7020" | |||||||||
| CAEN Financial Year |
7022
|
|||||||||
Comments - Eulogosprim Srl